MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF - Slideshow (NASDAQ:MNKD) 2026-07-30
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript